General
Preferred name
CYCLOBENZAPRINE
Synonyms
CYCLOBENZAPRINE HYDROCHLORIDE ()
Lisseril ()
TNX-102 ()
cyclobenzaprine HCl, Aptalis ()
Cyclobenzaprine (hydrochloride) ()
MK130 hydrochloride ()
Cyclobenzaprine HCl ()
Cyclobenzaprine-d3 (hydrochloride) (CRM) ()
MK-130 [As The Base] ()
NSC-78206 ()
Flexeril ()
NSC-173379 ()
Amrix ()
NSC-169900 ()
MK-130 HYDROCHLORIDE ()
MK-130 (AS THE BASE) ()
Ciclobenzaprina ()
Cyclobenzaprine-d6 (hydrochloride) ()
P&D ID
PD009638
CAS
6202-23-9
303-53-7
1184983-42-3
2748492-38-6
Tags
available
drug
Approved by
FDA
First approval
1977
Drug indication
cirrhosis of liver
Fibromyalgia
cerebral palsy
Post-traumatic stress disorder
Depression
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Cyclobenzaprine (MK130) hydrochloride is an orally active 5-HT2 receptor antagonist. Cyclobenzaprine hydrochloride acts centrally, providing skeletal muscle relaxation, alleviating muscle spasms, and reducing pain. Additionally, Cyclobenzaprine hydrochloride has antiprotozoal activity. Additionally, Cyclobenzaprine hydrochloride also possesses antiparasitic activity. Cyclobenzaprine hydrochloride holds promise for research in the fields of acute, painful skeletal muscle disorders and infectious diseases[1][2][3][4][5]
DESCRIPTION Cyclobenzaprine is a tricyclic antidepressant similar to . It acts as a skeletal muscle relaxant and central nervous system (CNS) depressant. (GtoPdb)
DESCRIPTION 5-HT2 serotonin receptor antagonist (LOPAC library)
DESCRIPTION Cyclobenzaprine is a skeletal muscle relaxant that works on the brainstem to treat muscle spasms of local origin. Cyclobenzaprine is indicated as a short-term adjunct therapy, along with rest and physical therapy, for relief of muscle spasm associated with acute, painful musculoskeletal conditions. (Enamine Bioactive Compounds)
Cell lines
0
Organisms
1
Compound Sets
23
Cayman Chemical Bioactives
15885
18027
39834
ChEMBL Approved Drugs
CHEMBL1200636
CHEMBL669
ChEMBL Drugs
CHEMBL1200636
CHEMBL669
Drug Repurposing Hub
DrugBank
DB00924
DrugBank Approved Drugs
DB00924
DrugCentral
751
DrugCentral Approved Drugs
751
DrugMAP
DMO1234
DM1YBRM
DrugMAP Approved Drugs
DM1YBRM
DrugMatrix
Enamine Bioactive Compounds
EBC-12731
Enamine BioReference Compounds
Guide to Pharmacology
7152
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL669
MedChem Express Bioactive Compound Library
HY-B0740
NCATS Inxight Approved Drugs
69O5WQQ5TI
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
cyclobenzaprine-hci
The Spectrum Collection
External IDs
73
Properties
(calculated by RDKit )
Molecular Weight
275.17
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
0
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
2
cLogP
4.55
TPSA
3.24
Fraction CSP3
0.2
Chiral centers
0.0
Largest ring
7.0
QED
0.68
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
5-HT2
Indication
spasms
Target
HTR2A
5-HT Receptor
Parasite
MOA
adrenergic receptor agonist, serotonin receptor agonist
Therapeutic Class
Antidepressants
Pathway
Anti-infection
GPCR/G protein
Neuronal Signaling
Source data